Pharma: an industry shaped by shareholder value

Jun 15, 2016
Big drug companies today have remade their business models.
Big Pharma has remade their business models over time to maximize shareholder value. 
Joe Raedle/Getty Images

Valeant Pharmaceuticals and the dark side of capitalism

Jun 10, 2016
Investors' demands for more profits left patients with the choice to pay up or die.
Howard Schiller, interim CEO of Valeant Pharmaceuticals International, and Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, listen during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC.

A push for more transparency in drug research costs

Feb 16, 2016
The industry worries it's a step toward price controls.
Drug companies are not only in the spotlight for price setting, but now they may be required to be transparent about R&D spending. 
Kiran Foster/Flickr